ADAR1 Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

ADAR1 Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150,532	Closed	-$3.24M	–	313
2025 Q4	$3.24M	Buy	+150,532	New	+$2.92M	0.24%	73
2024 Q4	–	Sell	-80,900	Closed	-$1.06M	–	226
2024 Q3	$1.06M	Buy	+80,900	New	+$1.23M	0.17%	70
2024 Q1	–	Sell	-2,000	Closed	-$28.2K	–	268
2023 Q4	$28.2K	Buy	+2,000	New	+$23.5K	0.01%	127

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

ADAR1 Capital Management's AVDL Position: Q1 2026 in Review

ADAR1 Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 150,532 shares — an estimated $3.24M sold.

ADAR1 Capital Management first reported a position in AVDL in Q4 2023 and held it in 3 quarters. The position peaked at $3.24M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

ADAR1 Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
ADAR1 Capital Management sold 150,532 Avadel Pharmaceuticals shares in Q1 2026, an estimated $3.24M.
ADAR1 Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2023 and held it in 3 quarters.
ADAR1 Capital Management's Avadel Pharmaceuticals position peaked at $3.24M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.